Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding

Exclusion Criteria

• •1. Patients were diagnosed with upper gastrointestinal bleeding by endoscopy caused by esophageal varices and portal hypertensive gastropathy, Mallory-Weiss syndrome, dieulafoy disease.
• •2. Pregnant women or breastfeeding women.
• •3. Patients who had undergone surgery because of ulcer complications or gastrectomy, gastrointestinal anastomosis within 30 days before the trial.
• •4. Patients were diagnosed with gastrinoma or gastric malignancy.
• •5. Patients had other associated complications, which may affect the efficacy.
• •6. Patients who like alcohol abuse, drug addicts or others which are not suitable for drug trials.
• •7. Patients who were allergic to any ingredient of any PPI and allergies.
• •8. Patients diagnosed with small vessel spurting who had to undergo endoscopic hemostasis or surgery or severe gastrointestinal bleeding.
• •9. Patients suffering from serious heart, brain, lung, liver, kidney disease or severe hypertension.
• •10. Patients who had coagulopathy, whose PT wasmore three seconds than normal controls, whose APTT\> 1.5 times the upper limit of normal or low-dose heparin treatment.
• •11. Patients whose systolic blood pressure less than 90mmHg or lower \> 30mmHg than the baseline systolic blood pressure, pulse pressure less than 20mmHg, hematocrit less than 20%.
• •12. Patients who participated in other clinical trials within three months before this trial.
• •13. Patients who need to use other drugs which may affect the trial during the trial or a week before the trial.
• •14. Patients who were considered unsuitable for selected candidates.